Uptake of biodegradable poly(γ-glutamic acid) nanoparticles and antigen presentation by dendritic cells in vivo

Results in Immunology

Volumn 3, Issue , 2013, Pages 1-9

  Uto, Tomofumi ^a,c   Toyama, Masaaki ^a,c   Nishi, Yosuke ^a,c   Akagi, Takami ^b,c   Shima, Fumiaki ^b,c   Akashi, Mitsuru ^b,c   Baba, Masanori ^a,c  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Dendritic cell; Drug delivery; Immune response; Nanoparticle; Vaccine

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; FLUORESCEIN ISOTHIOCYANATE; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NANOPARTICLE; OVALBUMIN; POLY(GAMMA GLUTAMIC ACID); POLYMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; BIODEGRADABILITY; CD8+ T LYMPHOCYTE; CELL MIGRATION; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; IMMUNE RESPONSE; IN VIVO STUDY; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN; SPLEEN CELL; UPREGULATION; WILD TYPE;

EID: 84872583396     PISSN: None     EISSN: 22112839     Source Type: Journal    
DOI: 10.1016/j.rinim.2012.11.002     Document Type: Article

References (33)

1. Plotkin SA Vaccines: past, present and future. Nature Medicine 2005, 11:S5-S11.
2. Coffman RL, Sher A, Seder RA Vaccine adjuvants: putting immunity to work. Immunity 2010, 33:492-503.
3. Peek LJ, Middaugh CR, Berkland C Nanotechnology in vaccine delivery. Advanced Drug Delivery Reviews 2008, 60:915-928.
4. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Medicine 1998, 4:397-402.
5. Letvin NL, Barouch DH, Montefiori DC Prospects for vaccine protection against HIV-1 infection and AIDS. Annual Review of Immunology 2002, 20:73-99.
6. Petrovsky N, Aguilar JC Vaccine adjuvants: current state and future trends. Immunology and Cell Biology 2004, 82:488-496.
7. Sato K, Fujita S Dendritic cells: nature and classification. Allergology International 2007, 56:183-191.
8. Steinman RM, Banchereau J Taking dendritic cells into medicine. Nature 2007, 449:419-426.
9. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003, 425:397-402.
10. Kawai T, Akira S The roles of TLRs, RLRs and NLRs in pathogen recognition. International Immunology 2009, 21:317-337.
11. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S Antigen presentation and T cell stimulation by dendritic cells. Annual Review of Immunology 2002, 20:621-667.
12. Uto T, Wang X, Sato K, Haraguchi M, Akagi T, Akashi M, et al. Targeting of antigen to dendritic cells with poly(γ-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. Journal of Immunology 2007, 178:2979-2986.
13. Wang X, Uto T, Akagi T, Akashi M, Baba M Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120. Journal of Virology 2007, 81:10009-10016.
14. Akagi T, Kaneko T, Kida T, Akashi M Preparation and characterization of biodegradable nanoparticles based on poly(γ-glutamic acid) with l-phenylalanine as a protein carrier. Journal of Controlled Release 2005, 108:226-236.
15. Uto T, Akagi T, Hamasaki T, Akashi M, Baba M Modulation of innate and adaptive immunity by biodegradable nanoparticles. Immunology Letters 2009, 125:46-52.
16. Uto T, Wang X, Akagi T, Zenkyu R, Akashi M, Baba M Improvement of adaptive immunity by antigen-carrying biodegradable nanoparticles. Biochemical and Biophysical Research Communications 2009, 379:600-604.
17. Himeno A, Akagi T, Uto T, Wang X, Baba M, Ibuki K, et al. Evaluation of the immune response and protective effects of rhesus macaques vaccinated with biodegradable nanoparticles carrying gp120 of human immunodeficiency virus. Vaccine 2010, 28:5377-5385.
18. Okamoto S, Matsuura M, Akagi T, Akashi M, Tanimoto T, Ishikawa T, et al. Poly(γ-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice. Vaccine 2009, 27:5896-5905.
19. Yamaguchi S, Tatsumi T, Takehara T, Sasakawa A, Yamamoto M, Kohga K, et al. EphA2-derived peptide vaccine with amphiphilic poly(γ-glutamic acid) nanoparticles elicits an anti-tumor effect against mouse liver tumor. Cancer Immunology and Immunotherapy 2010, 59:759-767.
20. Edelson BT, KC W, Juang R, Kohyama M, Benoit LA, Klekotka PA, et al. Peripheral CD103+ dendritic cells from a unified subset developmentally related to CD8α+ conventional dendritic cells. Journal of Experimental Medicine 2010;207:823-836.
21. Henri S, Poulin LF, Tamoutounour S, Ardouin L, Guilliams M, de Bovis B, et al. CD207+ CD103+ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells. Journal of Experimental Medicine 2010, 207:189-206.
22. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826.
23. Alvarez D, Vollmann EH, von Andrian UH Mechanisms and consequences of dendritic cell migration. Immunity 2008, 29:325-342.
24. Uto T, Akagi T, Toyama M, Nishi Y, Shima F, Akashi M, et al. Comparative activity of biodegradable nanoparticles with aluminum adjuvants: Antigen uptake by dendritic cells and induction of immune response in mice. Immunology Letters 2011, 140:36-43.
25. Uto T, Akagi T, Yoshinaga K, Toyama M, Akashi M, Baba M The induction of innate and adaptive immunity by biodegradable poly(γ-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway. Biomaterials 2011, 32:5206-5212.
26. Pamer E, Cresswell P Mechanisms of MHC class I-restricted antigen processing. Annual Review of Immunology 1998, 16:323-358.
27. Yoshikawa T, Okada N, Oda A, Matsuo K, Matsuo K, Mukai Y, et al. Development of amphiphilic γ-PGA-nano-particle based tumor vaccine: potential of the nanoparticulate cytosolic protein delivery carrier. Biochemical and Biophysical Research Communications 2008, 366:408-413.
28. Jelinek I, Leonard JN, Price GE, Brown KN, Meyer-Manlapat A, Goldsmith PK, et al. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. Journal of Immunology 2011, 186:2422-2429.
29. Topham DJ, Tripp RA, Doherty PC CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. Journal of Immunology 1997, 159:5197-5200.
30. Furmanov K, Elnekave M, Lehmann D, Clausen BE, Kotton DN, Hovav AH The role of skin-derived dendritic cells in CD8+ T cell priming following immunization with lentivectors. Journal of Immunology 2010, 184:4889-4897.
31. Shen CH, Talay O, Mahajan VS, Leskov IB, Eisen NH, Chen J Antigen-bearing dendritic cells regulate the diverse pattern of memory CD8 T-cell development in different tissues. Proceedings of the National Academy of Sciences 2010, 107:22587-22592.
32. Ingolotti M, Kawalekar O, Shedlock DJ, Muthumani K, Weiner DB DNA vaccines for targeting bacterial infections. Expert Review of Vaccines 2010, 9:747-763.
33. Pashine A, Valiante NM, Ulmer JB Targeting the innate immune response with improved vaccine adjuvants. Nature Medicine 2005, 11:S63-S68.